RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nektar Therapeutics Stock

Nektar Therapeutics Debt 2024

Nektar Therapeutics Debt

-35.28 USD

Ticker

NKTR

ISIN

US6402681083

WKN

165417

In 2024, Nektar Therapeutics's total debt was -35.28 USD, a -60% change from the -88.2 USD total debt recorded in the previous year.

Nektar Therapeutics Aktienanalyse

What does Nektar Therapeutics do?

"Answer: Nektar Therapeutics is an American biopharmaceutical company based in San Francisco, specializing in the discovery and development of drugs for the treatment of cancer, autoimmune, and chronic metabolic diseases. The company was founded in 1990 by CEO Howard Robin and his team, initially focused on researching new technologies for drug development and later shifted to developing drugs for cancer therapy. Nektar Therapeutics has a unique business model that involves partnering with major pharmaceutical companies and other partners to develop a wide range of products, which are then licensed to these partners for commercialization and distribution. The company operates in several sectors, including oncology, pain management, autoimmune diseases, and metabolic diseases. Its important products include Movantik for opioid-induced constipation and ONZEALD for pancreatic cancer treatment. Nektar Therapeutics has made significant progress in developing immunoncology drugs, with potential projects such as NKTR-214 for advanced skin cancers. With its leading position in innovative drug development and strategic partnerships, the company has the potential to become a major player in cancer therapy." Nektar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Nektar Therapeutics's Debt Structure

Nektar Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Nektar Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Nektar Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Nektar Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Nektar Therapeutics stock

What is the debt of Nektar Therapeutics this year?

Nektar Therapeutics has a debt level of -35.28 USD this year.

What was the debt of Nektar Therapeutics compared to the previous year?

The debt of Nektar Therapeutics has increased by -60% compared to the previous year dropped.

What are the consequences of high debt for investors in Nektar Therapeutics?

High debt can pose a risk for investors of Nektar Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Nektar Therapeutics?

Low debt means that Nektar Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Nektar Therapeutics affect the company?

An increase in debt of Nektar Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Nektar Therapeutics affect the company?

A reduction in debt of Nektar Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Nektar Therapeutics?

Some factors that can influence the debt of Nektar Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Nektar Therapeutics so important for investors?

The debts of Nektar Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Nektar Therapeutics take to change the debt?

To change the debt, Nektar Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Nektar Therapeutics pay?

Over the past 12 months, Nektar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nektar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nektar Therapeutics?

The current dividend yield of Nektar Therapeutics is .

When does Nektar Therapeutics pay dividends?

Nektar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nektar Therapeutics?

Nektar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nektar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nektar Therapeutics located?

Nektar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nektar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nektar Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Nektar Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Nektar Therapeutics in the year 2023?

In the year 2023, Nektar Therapeutics distributed 0 USD as dividends.

In which currency does Nektar Therapeutics pay out the dividend?

The dividends of Nektar Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Nektar Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Nektar Therapeutics

Our stock analysis for Nektar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nektar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.